Differing effects of oral and transdermal hormone replacement therapy on cardiovascular risk factors in healthy postmenopausal women

Am J Cardiol. 2003 Jul 15;92(2):212-4. doi: 10.1016/s0002-9149(03)00542-3.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Cutaneous*
  • Administration, Oral*
  • Age Factors
  • Blood Glucose / analysis*
  • Blood Glucose / drug effects*
  • C-Reactive Protein / analysis*
  • C-Reactive Protein / drug effects*
  • Cardiovascular Diseases / blood*
  • Cardiovascular Diseases / prevention & control*
  • Contraceptives, Oral, Combined / administration & dosage*
  • Contraceptives, Oral, Combined / pharmacology*
  • Contraceptives, Oral, Combined / therapeutic use
  • Drug Combinations
  • Estradiol / administration & dosage*
  • Estradiol / pharmacology*
  • Estradiol / therapeutic use
  • Estriol / administration & dosage*
  • Estriol / pharmacology*
  • Estriol / therapeutic use
  • Estrogen Replacement Therapy*
  • Female
  • Humans
  • Hypoglycemic Agents / blood*
  • Insulin / blood*
  • Lipids / blood*
  • Middle Aged
  • Norethindrone / administration & dosage*
  • Norethindrone / analogs & derivatives*
  • Norethindrone / pharmacology*
  • Norethindrone / therapeutic use
  • Reference Values
  • Risk Factors

Substances

  • Blood Glucose
  • Contraceptives, Oral, Combined
  • Drug Combinations
  • Hypoglycemic Agents
  • Insulin
  • Lipids
  • estradiol, norethindrone drug combination
  • Estradiol
  • netagen
  • Trisequens
  • C-Reactive Protein
  • Estriol
  • Norethindrone